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Since its initial appearance in 1985, human immunode-
ficiency virus (HIV) infection and its late- stage manif-
estation, the acquired immune deficiency syndrome
(AIDS) have affected a growing number of persons
across Korea and around the globe 1) . Worldwide, by the
end of the year 2000, 36.1 million persons are living with
AIDS, and an estimated 21.8 million had died since the
beginning of the epidemic.
As of Decembe r 2000, more tha n 1,280 HIV inf-
ections a nd 286 deaths from AIDS in Korea have
bee n re ported to the Korea n Nationa l Institute of
Hea lth (Korea n Ministry of Hea lth a nd Welfa re ,
2000). The number of cases includes only the repo-
rted cases , but the factua l numbe r is pres umed to
be at least three to five times la rge r. The e pide mic
in As ia n countries , particula rly India a nd Tha iland,
has lagged te mpora lly be hind that in Africa ;
howeve r, the numbe r of new cases in this region
is acce le rating ra pidly, a nd the magnitude of the
e pidemic is projected to exceed that of sub- Saharan
Figure 1. Cumulative prevalence of HIV infection in Korea
from 1985 to 2000. The number of new cases are
persistently increasing each year.(Korean Ministry of Health
and Welfare , 2000)
Africa in the early pa rt of the twe nty- first century2 ) .
In Korea , the incide nce of new infections a re pe rs i-
ste ntly increas ing each yea r(Figure 1).
Age a nd S e x Dis t rib ut ion of HIV Infe ct io n
in Ko re a
The a ge distribution of HIV- infected individua ls
in Korea is 0.4% in 0- 9 yea rs , 2.2% in 10- 19
ye a rs , 3 1.7% in 20- 29 yea rs , 36.0% in 30- 39
ye a rs , 18.3% in 40- 49 yea rs , 8.6% in 50- 59 ye a rs
a nd 2.9% in ove r 60 ye a rs of a ge . Among the
tota l numbe r of 1,280 cas es in Kore a , ove r 60%
a re in the age ra nge of 20 to 39 which is the
most s ocioeconomica lly a ctive a ge . Ma le to
fe ma le ratio is 7:1 (fe ma le , 12.5%). The proportion
of wome n a mong US AIDS cas es ha s increa se d
a nnua lly, from 10% in 1988, to 19% in 1995, to
23% in 19993 ) . In US , the predomina nt expos ure
for wome n is attribute d prima rily to s ex with a
ma le IDU3 ) , while in Korea , it is attributed prima rily
to hete ros exua l conta ct with a n infe cte d s pouse
or pa rtne r. In both settings , wome n may be
unawa re of the ir own ris k a nd thus may be
difficult to ide ntify a nd ta rget for preve ntion
inte rve ntions . This is why the HIV e pide mic in
wome n is complex from a preve ntion sta ndpoint,
a nd the proportion of wome n is expe cte d to
incre ase cons iste ntly.
T ra ns mis s io n Ro ute of HIV Infe c t io n in
Ko re a
While the majority of cumulative HIV infections
have occurred in traditiona l high- ris k groups , inclu-
ding me n who have sex with me n (MSM) a nd
injection drug use rs (IDUs), persons in othe r ris k
categories now account for a greate r proportion of
AIDS cases tha n in yea rs past4 ) . For instance ,
hete rosexua l tra ns miss ion of HIV has become the
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domina nt ca use of new infections a mong wome n3 ) .
Racia l a nd ethnic minorities re prese nt a n increased
proportion of AIDS cases 5 ) . In Korea , 82% of the
tra ns mis s ion is by sexua l contact, a mong which
hete rosexua l contact constitutes 72% a nd homo-
sexua l contact 28%. As the major mode of tra ns-
miss ion in Korea a ppea rs to be hete rosexua l con-
tact, rathe r tha n IDU or homosexua l contact, this
s uggests the pote ntia l for wides pread dis pe rs ion in
the ge ne ra l population (Figure 2). Until 1992 most
of the sexua l contact that was highly like ly to be
res pons ible for acquiring infection was from outs ide
of the country, but afte r 1992, this tre nd sta rted to
s hift to the oppos ite . Othe r routes of tra ns miss ion
a re by tra nsfus ion of blood a nd blood products ,
which is 3.0%, a nd by the pe rinata l route 0.2%
(Figure 2).
Figure 2 . Modes of transmission of HIV infection in
Korea. Heterosexual contact is the major trans mission
route in Korea. (Korean Ministry of Health and Welfare ,
2000)
The re has been only one case of tra ns miss ion
by IDU in Korea until now (unpublis hed data). IDU
tra ns miss ion is rare in Korea pe rhaps beca use
Korea n pha rmacies se ll syringes without a doctor s
prescription.
HIV S ubtype in Kore a
Viruses have been orga nized into three major
groups : group M, which is most common in the
Ame ricas abd group O a nd group N which are
most commonly see n in Africa6 ) . Group M HIV- 1
viruses a re furthe r divided into s ubtypes A through
J , of which s ubtype B is most common in north
a nd south Ame rica , Europe , Austra lia a nd the
Ca rribea n. C type is most common in Africa a nd
southeast As ia 7 ) .
In a study of molecular ana lys is of HIV- 1 in
South Korea us ing the nef ge ne as an epide mio-
logic ma rke r, phyloge netic a na lys is indicated that a
majority of Korea n ca rrie rs we re infected with
s ubtype B, whe reas three exa mples for s ubtype A
a nd one for s ubtype D we re a lso ide ntified8 ) . Most
of the s ubtype B seque nces from this South Kor-
ea n study population was see n to form a mono-
phyletic clade 8 ) . Until now, s ubtype A, B, C, D, E,
a nd G of HIV- 1 have a ll bee n introduced into
Korea 9 ) .
A IDS- re la te d Oppo rtunis t ic Infe ct io ns a nd
Ma ligna nc ie s in Ko re a
Highly active a nti- retrovira l thera py (HAART) has
a llowed a decrease in the incidence of opportunistic
infections (OIs) a nd Ka pos i s sa rcoma in HIV
- infected individua ls with low CD4+ T ce ll counts .
The most common OIs of AIDS a re Pneum ocys tis
carinii pne umonia (PCP), disse minated Mycobact-
e rium avium complex, esophageal candidiasis , Cyto-
mega lovirus (CMV) retinitis a nd disease, a nd
Kapos i s sa rcoma 1 0 ) . The s pectrum of HIV- re lated
opportunistic diseases in Korea has bee n investi-
gated in 2 la rge studies . In 1999, Oh et a l. re por-
ted that tuberculos is (25%) was the most freque ntly
obse rved OI, followed by ca ndidias is (21%), he rpes
zoste r (20%), PCP (10%) a nd CMV disease (9.8%).
Toxoplas mos is was not found 1 1) . This finding of
high preva le nce of tube rculos is in AIDS patients
may be s peculated by the e pide miologic cha racter-
istics of Korea in that tuberculos is has long been
a n e ndemic disease in this country. Howeve r, more
rece ntly, Kim et a l. reported that the most
freque ntly obse rved OI in Korea was PCP (2 1%),
followed by tube rculos is (17%) a nd CMV infection
(12%)1 2 ) (Ta ble 1). This unexpected obse rvation that
PCP was one of the most importa nt HIV- re lated
infections in Korea, as it is in other western countr-
ies , was a n interesting finding. The most common
ca use of death in Korea was tube rculos is and PCP
(Ta ble 2). Common AIDS- re lated ma ligna ncies in
Korea are lymphoma (1.7%) a nd Ka pos i"s sa rcoma
(1.1%)12 ) .
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Table 1. Oppo rtunis tic Dis e as e s of 12 1 HIV- infe cte d Pe rs o ns (n=3 17 Cas e s )
Opportunistic Diseases
No. of
Cases (%)
Mean CD4+Cell
Count (/mm3)
Mean HIV RNA
(copies/mm3)
Mean 2MG
(mg/L)
Candidiasis 50(28.4) 71 338,474 3.6
Oral 6(20.5) 77 415,274 3.5
Esophageal 14(7.9) 57 141,000 3.7
PCP 37(21.0) 63 281,967 3.2
Oral hairy leukoplakia 30(17.0) 206 236,295 3.2
Tuberculosis 29(16.5) 142 817,012 3.7
Pulmonary 8(10.2) 162 833,158 3.1
Extrapulmonary 11(6.3) 89 807,786 5.1
Folliculitis 22(12.5) 186 345,896 3.2
CMV infection 21(11.9) 32 204,093 4.1
Retinitis 15(8.5) 28 - 3.7
Other infections* 6(3.4) 37 204,093 4.4
HIV wasting syndrome 15(8.5) 67 139,890 3.9
Dermatophytosis 11(6.3) 254 355,789 4.5
HIV encephalopathy 9(5.1) 80 798,552 3.8
Herpes zoster 9(5.1) 247 46,191 3.1
Peripheral neuropathy 8(4.5) 79 24,701 4.1
Seborrheic dermatitis 7(4.0) 120 136,641 3.3
MOTT infection 6(3.4) 51 182,630 4.7
Syphilis 6(3.4) 604 239,742 3.4
Cryptococcal meningitis 4(2.3) 88 - 2.2
HIV myopathy 3(1.7) 109 - 3.7
HSV, chronic ulcer 3(1.7) 80 144,364 3.4
Toxoplasmosis , brain 3(1.7) 21 - 4.9
Malignant lymphoma 3(1.7) 46 1,422 5.4
Abscess 3(1.7) 236 261,724 2.6
Kaposi's sarcoma 2(1.1) 198 541,913 3.7
PML 2(1.1) 183 254,297 3.7
Acute pancreatitis 2(1.1) 27 260,000 2.9
Periodontitis 2(1.1) 63 19,097 3.0
Molluscum contagiosum 2(1.1) 35 51,442 2.6
Cervix cancer 1(0.6) 266 17,742 3.4
Eccrine gland cancer 1(0.6) 374 - 5.2
Spinal myelopathy 1(0.6) 272 - 2.7
Rectal cancer 1(0.6) 56 - 2.8
Clonorchiasis 1(0.6) 50 1,422 7.8
Neurocysticercosis 1(0.6) 3 - -
PCP; pne umocystis ca rinii pne umonia , CMV; cytomega lovirus , HIV; huma n immunodefic ie ncy virus , HSV; herpes
s implex virus , PML; progress ive multifocal le ukoe ncepha lopathy, MOTT; mycobacteria othe r tha n tuberculos is
*: lung, esophagus , stomach, a nd colon infections
- : not done
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Table 2 . Caus e s of De ath in 35 Exp ire d HIV- infe cte d
Pe rs o ns (n=35 Cas e s )
Cause of Death No. of Cases (%)
Tuberculosis 9(25.7)
Pulmonary 6(17.1)
Extrapulmonary 3(8.6)
PCP 9(25.7)
Bacteria l pneumonia 7(20.0)
HIV encephalopathy 3(8.5)
Cryptococcal meningitis 2(5.7)
Malignant lymphoma 2(5.7)
Sepsis 1(2.9)
Toxoplasmosis , brain 1(2.9)
Myocardial infarction 1(2.9)
PCP; pneumocystis ca rinii pneumonia , HIV; huma n im-
munodeficiency virus
Ant i- re t rovira l Tre a t me nt Re g ime ns a nd
Re s po ns e in Kore a
Zidovudine is the first a nti- retrovira l drug that
was introduced into Korea . This drug is s upplied
free to patie nts by the gove rnme nt. Dida nos ine was
cove red by ins ura nce from 1994, and la mivudine
a nd indinavir from 1998. HAART has bee n a pplied
Table 3 . Me tabo lic parame te rs in HIV- infe cte d ind iv idua ls and he a lthy co ntro ls .
HIV- infected individuals
HAART- experienced
(n=57)
HAART- naive
(n=42)
Healthy controls
(n=57)
Total cholesterol (mg/dl)
Triglyceride (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
Free fatty acid (Eq/L)
Apo A1 (mg/dl)
Apo B (mg/dl)
Glucose (mg/dl)
Insulin (IU/ml)
C- peptide (ng/ml)
Insulin resistance (mmol2/l2)
Leptin (ng/ml)
Cortisol (g/dl)
DHEA (ng/ml)
158.1±20.2
148.3±22.7
31.7± 1.4
96.3± 10.3
352.1±63.3
100.1± 16.4
79.5± 14.7
96.4±6.1
10.8±4.2
3.4±0.7
2.6±0.8
3.2±3.1
8.9±2.8
5.1±4.1
152.6±16.8
139.3±12.1
32.7±2.1
91.5±11.3
339.2±59.3
102.3±24.2
77.9±18.4
92.5±7.1
8.9±1.9
3.1±0.8
2.1±0.4
2.9±2.3
8.8±2.6
5.8±3.1
156.2± 18.0
121.3±9.3
38.4± 1.9
95.2±9.4
-
-
-
98.0±8.2
9.2± 1.0
2.9±0.3
2.3±0.3
-
9.1±3.0
4.8±2.8
Data a re mea ns ± SD. Statistical a nalys is was done by ana lys is of va ria nce (ANOVA) methods a nd multiple
compa rison a nalys is (LS D) of the SAS syste m. The re is no statistica l diffe re nce in the metabolic pa ra mete rs
betwee n the three groups of individua ls (p>0.05).
HAART; highly active a ntiretrovira l therapy, HIV; huma n immunodeficiency virus , HDL; high de ns ity lipoprote in, LDL;
low de ns ity lipoprote in, Apo; apolipoprote in, DHEA; de hydroepia ndroste rone
to patie nts for ove r 3 years in Korea with va rious
regime ns . The re a re 9 ava ila ble drugs in Korea,
which a re zidovudine , la mivudine, dida nos ine ,
stavudine , za lcita bine , efavire nz, ne lfinavir, ritonavir
a nd indinavir. Patie nts who a re e nrolled with the
gove rnme nt are s upplied with HAART a nd othe r
medica l fina ncia l s upport (restricted to ins ura nce
cove rage ite ms) by the gove rnme nt.
The most commonly used HAART regime n in
Korea is two nucleos ides combined with a protease
inhibitor. A study of Korea ns with a triple combi-
nation the rapy, including zidovudine , dida nos ine ,
la mivudine a nd indinavir, has a n effect of lowe ring
the level of HIV RNA to non- detecta ble ra nge of
less than 500 copies/ml at 1 month in 70% a nd at
12 months in 90% of the Korea n patie nts . The
mea n CD4+ T cell count of 206/mm3 rose to
376/mm3 afte r 12 months of treatme nt13 ) .
Adve rs e Effe ct s of HAA RT in Kore a
With the increas ing usage of HAART, va rious
adve rse effects a re be ing expe rienced in HIV-
infected individua ls . Common adverse effects of
triple combination the ra py, including zidovudine,
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la mivudine, dida nos ine a nd indinavir, in Korea ns a re
asymptomatic indirect hype rbilirubine mia , fla nk pa in,
na usea , fatigue and headache . Skin ras h, a bdo-
mina l discomfort a nd e levation of tra nsa minases
a re some ra re complications in Koreans 13 ). Lipo-
dystrophy, hype rlipide mia a nd hype rins uline mia a re
common meta bolic complications of HAART in
HIV- infected individua ls 14 ). Protease inhibitors (PIs)
ca n ca use hype rglyce mia , hype rins uline mia , ins ulin
res ista nce , hyperlipidemia a nd lipodystrophy.14 ,15 )
One of the la rgest studies of P I- induced lipodyst-
rophy re ported a n 83% preva le nce rate with a n
11% incide nce of seve re lipodystrophy.14 ) Anothe r
rece nt study re ported a 13% cumulative incide nce
of new onset lipodystrophy in a 5- yea r cohort
study.15 ) However, in the la rgest meta bolic compli-
cation study in Korea , lipodystrophy was found in
only 3.5% of patie nts who we re on HAART for a
mea n duration of 25 months 16 ). Lipid alte rations
associated with AIDS are known as hype rtriglyc-
e ride mia , high free fatty acid, low HDL a nd LDL
cholesterols 17 ). P I use a re cha racte rized by increase
of se rum triglyce ride , ra nging from 12.9% to 80%,
a nd increase of LDL choleste rol without a melio-
rating low HDL18 ,19 ). Howeve r, triglyce ride , tota l ch-
oleste rol, LDL a nd HDL cholesterol, FFA, ApoA1,
ApoB, glucose, insulin, c- peptide, leptin, cortisol a nd
DHEA were not influe nced by HAART in
Korea ns 16 )(Ta ble 3). These findings wa rra nt furthe r
race- s pecific meta bolic complication studies in HIV-
infected s ubjects rece iving HAART. Osteoporos is is
a rece ntly recognized clinica l feature in HIV infec-
tion that needs to be cla rified through more inves-
tigations of whethe r it is a n effect of HIV infection
itse lf or a n adve rse effect of HAART. Osteoporos is
a nd osteope nia we re exa mined in Korea ns in a
rece nt study, a nd s howed res ults of no re leva nce
of e ithe r HIV infection or drug in Korea ns2 0 ) .
Ge notypic Re s is ta nce of Ant i- re t rovira l
Drugs in Kore a ns
The decreases in incidence of AIDS- related
opportunistic illnesses and declining morta lity a mong
HIV- infected pe rsons have been la rgely attributed
to the ava ila bility of HAART. Howeve r, our a bility to
s usta in these adva nces a mong HIV- pos itive pe rs-
ons is threate ned by the e merge nce of a nti-
retrovira l drug res ista nce .
Ge notypic res ista nce of a nti- retrovira l drugs in
Korea ns was investigated in a cross- sectiona l study
conducted with 41 HIV- infected Korea ns (29 naïve
a nd 12 HAART- expe rie nced for a mea n duration of
11.3 months) from Octobe r 1999 to Se pte mber
2000 in a n outpatie nt clinic of a unive rs ity hos pita l
a nd the Korea n Nationa l Institute of Hea lth. The
e ntire protease ge ne a nd 250 a mino acids of the
reve rse transcriptase (RT) ge ne we re a mplified a nd
seque nced. Ana lys is was done by DNASTAR a nd
the progra m was s upported by HIV RT a nd
Protease Sequence Stanford Database (HRP- ASAP).
Prima ry res ista nce to nucleos ide a na logue reve rse
tra nscriptase inhibitors (NRTIs) was obse rved in 4
out of 29(14%) naïve individua ls , whe reas primary
res ista nce to protease inhibitors (PIs) was found in
none of naïve individua ls . The freque ntly involved
codons in NRTI res ista nce were at pos itions
4 1(50%), 69 (50%), and 215(50%). In HAART-
experie nced individuals , the preva le nce for prima ry
res ista nt ge notypes was 42% for NRTIs and 25%
for PIs . The most freque nt NRTI mutations occur-
red at codons 184(42%) a nd 41(17%), whe reas the
most common P I res ista nce mutation was at
codons 82(17%) and 48(8%). Some atypica l a mino
acid changes s uch as M41I, D67G, T69A, M184I/R,
G 190K, L2 10M of the RT a nd L10M, K20I, G48R,
L63A/I/T, G73S , V82I of the protease ge ne we re
detected in HIV- infected Korea ns . Codon 63 may
not be associated with res ista nce in Korea ns but
only a typica l cha racte ristic of the Korea n isolates
s ince L63A/ I/T mutation in the protease ge ne was
detected in 93% of naïve a nd HAART- expe rienced
Korea ns . Res ista nce was detected 3 times more
freque ntly in the RT ge ne a nd more freque ntly in
the protease gene in the HAART- experienced com-
pa red to the naïve Korea ns . Ge notypic res ista nce
may be useful prior to the introduction of HAART
in Korea . S ince Korea n isolates have some unique
cha racteristics in ge notypic res istance , phe notypic
res ista nce a nd clinica l corre lation a re to be cons id-
e red for the eva luation of the effects of s pecific
drugs .
Several studies have demonstrated that resistance
testing improves virologic res ponse to second- line
HAART regime ns among HIV- infected persons who
have fa iled initia l empiric the ra py, a nd the preva l-
e nce of res ista nce mutations or res ista nce phe no-
types among drug- naïve pe rsons is ge ne ra lly low2 1).
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Howeve r, eve ntual recomme ndations rega rding re-
s ista nce screening to inform the choice of initia l
HAART regime n de pe nd large ly on the preva le nce
of res istance among HAART- naïve pe rsons , so
ongoing s urve illa nce of res ista nce in treatme nt-
naïve populations is critica l.
Co nc lus ion
HIV infection is pe rs istently increas ing in Korea .
The most common tra ns miss ion route is by sexua l
contact a nd the nota ble diffe rence of tra ns miss ion
route in Koreans is that HIV infection by IV drug
a buse is very ra re . Investigations on the treatment
res ponse of HAART s hows that triple combination
the ra py in Korea ns a ppea red to be ge nera lly we ll
tole rated, a nd was a ble to profoundly s usta in
s uppress ion of plas ma HIV- RNA to undetectable
leve ls in most patie nts . A nota ble cha racte ristic
finding of the adve rse effect of HAART in Korea ns
is that lipodystrophy was obse rved in only 3.5% of
the patie nts on HAART, a nd hype rlipide mia or
ins ulin res ista nce was not found. Since genotypic
res ista nce was detected in 14% of NRTI naïve
Korea ns , res ista nce testing may be useful prior to
the introduction of HAART in Korea.
HIV infection in Korea has some unique features
which are diffe re nt from those of other races or
countries . For a more deta iled a nd definite ide nti-
fication of the diffe re nces , a pros pective ly des igned
investigation on a la rge r sca le is necessa ry, which
will eve ntua lly ena ble bette r the ra pe utic a nd epid-
e miologic strategy for HIV infection/AIDS in this
country.
Refe re nce s
1. UNAIDS/WHO globa l AIDS statistics . AIDS Care 11
(2):253-264, 1999
2. Fa uci AS . The AIDS ep idem ic. Considerations for
the 2 1s t century. N Engl J Med 34 1:1046- 1050, 1999
3. Wortley P, Fleming P. AIDS in women in the United
S tates. Recent trends. JAMA 278:9 11-9 16, 1997
4. Centers for Disease Control and Prevention. US HIV
and AIDS cases rep orted through December 1999.
HIV/AIDS S urveillance Report 11(2):1-42, 1999
5. Ros e nbe rg P, Bigga r R. Trends in HIV incidence
am ong y oung adults in the Unite d S tates . JAMA
279:1894- 1899, 1998
6. Sulliva n P, Do A, Elle nbe rger D. Hum an imm unod-
eficiency virus (HIV) s ubtype surveillance of African-
born p ersons at risk for group O and group N HIV
infections in the United S tates. J Infect Dis 18 1:463-
469, 2000
7. J oint Unite d Natio ns P rogra mme on HIV/AIDS
(UNAIDS). Report on the global HIV/AIDS epidemic,
June 2000. Geneva, 2000
8. Kang MR, Cho YK, Chun J , Kim YB, Lee IS, Lee HJ ,
Kim S H, Kim YK, Yoon KJ , Ya ng J M, Kim J M,
S hin YO, Ka ng C, Lee J S , Choi KW, Kim DG,
Fitch WM, Kim SY. Phylogenetic analysis of the nef
gene re veals a dis tinctive m onophy letic clade in
Korean HIV- 1 cas es. J Acquir Imm une Defic Syndr
17:58- 68, 1998
9. Oh MD, Choe K. Epidem iology of HIV infection in
the Republic of Korea. J Korean Med Sci 14:469-
474, 1999
10. Palle la FJ, Delaney KM, Moorman AC, Loveless MO,
Fuhre r J , Satte n GA, Aschma n DJ , Holmberg SD.
Declining m orbidity and m ortality am ong patients
with advanced human immunodeficiency virus infection.
N Engl J Med 338:853-860, 1998
11. O h MD, Pa rk SW, Kim HB, Kim US , Kim NJ ,
Choi HJ , Shin DH, Lee J S, Choe K. Sp ectrum of
opportunis tic infections and malignancies in patients
with human immunodeficiency virus infection in South
Korea. Clin Infect Dis 29:1524- 1528, 1999
12. Kim J M, Cho GJ , Hong SK, Chung JS, Chang KH,
Kim CO , Cho J H, Pa rk YS , Kim HY, Choi YH,
Song YG. Characteristics of epidem iology and clini-
cal features of HIV infection/AIDS in Korea (in press).
13. Hong S K, Pa rk YS , Cho J H, Roh HJ , Kim HY,
Cha ng KH, Song YG, Kim J M. Antiviral effect and
safety of trip le combination therapy in hum an imm -
unodeficiency virus (HIV)- infected pers ons. Korean
J Med 58:582- 589, 2000
14. Carr A, Sa ma ras K, Thorisdottir A, Ka ufma nn GR,
Chis holm DJ , Coope r DA. Diagnos is , p re diction,
and natural course of HIV- 1 proteas e inhibitor-ass -
ociated lip odystrophy, hyperlipidem ia and diabetes
m ellitus : a cohort s tudy . Lance t 353: 2093-2 099,
1999
15. Ts iodras S , Ma ntzoros C, Hamme r S, Sa more M.
Effects of proteas e inhibitors on hyp ergly cem ia,
hyp erlip idemia, and lip odystrophy . Arch Intern Med
160:2050-2056, 2000
16. Cha ng KH, Kim J M, Hong SK, Song YG, Lee HC,
Lim S K. Does race p rotect an oriental p op ulation
from developing lipodys trophy in HIV- infected indivi-
duals on HAAR T? 8 th Conference on Retrovirus es
and Opportunis tic Infections. 2001 Abs t. 648, p .238
6
Characteristics of HIV Infection/AIDS in Korea
17. Grunfeld C, Pang M, Doerrler W, S higenaga JK,
Jens en P, Feingold KR. Lipids , lipoprote ins , triglyc-
eride clea ra nce a nd cytokines in huma n immunod
efic ie ncy virus infection a nd the acquired immuno
deficiency syndrome. J Clin Endocrinol Metab 74:1
045- 1052, 1992
18. Ca meron DW, Heath- Chiozzi M, Da nne r S. Rand-
om iz ed placebo-controlled trial of ritonavir in adva-
nced HIV- 1 dis eas e. Lancet 35 1:543-549, 1998
19. Mulligan K, Grunfeld C, Tai VW. Hyperlipidemia and
ins ulin resis tance are induced by proteas e inhibitors
independent of changes in body composition in pati-
ents with HIV infection. J Acquir Imm une Defic Sy -
ndr 23:35-43, 2000
20. Cha ng KH, Kim J M, Hong SK, Song YG, Lee HC,
Lim SK. Does race influence bone mineral density
in HIV- infected individuals receiving HAAR T? 8 th
Conference on Retrovirus es and Opp ortunis tic Infect-
ions. 2001 Abs t. 630, p.233
2 1. Little S , Daa r E, D"Aquila R. Reduced antiretroviral
drug s usceptibility am ong patients with primary HIV
infection. JAMA 282 :1142- 1149, 1999
7
